SCHEMBL1603757

SCHEMBL1603757

O=[N+]([O-])c1cc(O)ccc1C=Cc1ccc(O)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 7/20 0.57
EGFR P00533 2/20 0.51
FBP1 P09467 1/20 0.51
PTGS2 P35354 2/20 0.50
PTGS1 P23219 1/20 0.50
KDM4A O75164 1/20 0.49
KDM4B O94953 1/20 0.49
NPC1 O15118 1/20 0.49
MTOR P42345 1/20 0.49
PELI1 Q96FA3 1/20 0.46
APP P05067 2/20 0.45
MAPT P10636 2/20 0.45
PTPN1 P18031 1/20 0.45
MITF O75030 1/20 0.45
RECQL P46063 1/20 0.45
RAB9A P51151 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1603756 1.00 BACE1 (0.57) BACE1EGFRFBP1PTGS2PTGS1
SCHEMBL1405731 0.89 PTGS2 (0.58) BACE1EGFRFBP1PTGS2PTGS1
SCHEMBL1405729 0.89 PTGS2 (0.58) BACE1EGFRFBP1PTGS2PTGS1
SCHEMBL17609111 0.83 BACE1 (0.74) BACE1EGFRFBP1NPC1MAPT
SCHEMBL17625642 0.83 BACE1 (0.74) BACE1EGFRFBP1NPC1MAPT
SCHEMBL11848350 0.81 BACE1 (0.50) BACE1EGFRPTGS2MAPTNPSR1
SCHEMBL11848355 0.81 BACE1 (0.50) BACE1EGFRPTGS2MAPTNPSR1
SCHEMBL2002544 0.79 ERN1 (0.53) BACE1EGFRMAPT
SCHEMBL9658649 0.79 MAPT (0.64) BACE1EGFRPTGS2NPC1MAPT
SCHEMBL9658637 0.79 MAPT (0.64) BACE1EGFRPTGS2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242144-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US claimed
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases RESVERLOGIX CORP. 2011-04-07 US claimed
US-7846915-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases Resverlogix Corporation (CA) 2010-12-07 US claimed
US-8242144-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases RESVERLOGIX CORP. 2011-04-07 US disclosed
US-7846915-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases Resverlogix Corporation (CA) 2010-12-07 US disclosed
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045010-A2 STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases APOB, APOL1, HDLBP BACE1 1251/4885EGFR 4410/4885FBP1 1395/4885
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases APOB, APOL1, HDLBP BACE1 1251/4885EGFR 4410/4885FBP1 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.